Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Kansas Medical Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
Males and females age ≥ 18 years
Patients with breast cancer, lung cancer, malignant melanoma or who have undergone stem cell transplant or chimeric antigen receptor (CAR) T cell therapy for a hematologic malignancy.
Other cancer types including hematologic malignancies may be allowed if they are receiving treatments outlined in section 4.1.4
Solid Tumor patients and those with hematologic malignancies: Currently receiving active anti-cancer therapy, or planned to start within 14 days, with intravenous cytotoxic chemotherapy (oral or intravenous), intravenous chemoimmunotherapy combination, immunotherapy alone, an oral CDK 4/6 inhibitor. (This does not apply to recipients of stem cell transplant and CAR T therapy)
Therapy may be neo/adjuvant or for metastatic disease
Eastern Cooperation Oncology Group (ECOG) Performance status (PS) of 0-2
You may not be if
\* Life expectancy of \< 12 months
Clareo Health | To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment
